The data showed that the compounds under investigation influenced tumor cell growth differentially, demonstrating the BRCA1-null ovarian cancer cell line UWB1.289 to be significantly more sensitive to the antiproliferative effects of the investigated compounds than the respective BRCA1-wild type UWB1.289 + BRCA1 ovarian cancer cell line (t-test, p < 0.001). This evidence concerns the gene BRCA1 and ovarian cancer.